Our board

The BIA’s Board is drawn from a wide range of member companies. The Board currently comprises 11 Members, each of whom has been elected for a three-year term, after which they are invited to put themselves forward for re-election.

The BIA’s Board is drawn from a wide range of member companies. The Board currently comprises 11 Members, each of whom has been elected for a three-year term, after which they are invited to put themselves forward for re-election.

Board Members

Chair of the Board

Dr Dan Mahony

Dr Dan Mahony

Chair, BIA Board

Corporate Members

Anna Williamson

Anna Williamson

Executive Director , Roche Pharma Partnering

Charlotte Casebourne

Charlotte Casebourne

CEO, Theolytics

Claire Thompson

Claire Thompson

CEO, Agility Life Sciences

Ian McCubbin CBE

Ian McCubbin CBE

Chair of Cell and Gene Therapy Catapult, Chair of RoslinCT

Laura Lane

Laura Lane

Vice President, Lilly Ventures (Head of Europe), Eli Lilly and Company

Lisa Anson

Lisa Anson

CEO, Redx Pharma

Nerida Scott

Nerida Scott

Head of Johnson & Johnson Innovation, EMEA, Johnson & Johnson

Olivia Cavlan

Olivia Cavlan

Chief Corporate Development & Strategy Officer, Alchemab Therapeutics

Ros Deegan

Ros Deegan

CEO, OMass Therapeutics

Shaun Grady

Shaun Grady

SVP Business Development Operations, AstraZeneca

Sunil Shah

Sunil Shah

CEO, o2h Ventures

Associate Members

Dr Peter Finan

Dr Peter Finan

Partner, Epidarex Capital

Clare Terlouw

Clare Terlouw

Head of LifeArc Ventures, LifeArc

Melanie Toyne-Sewell

Melanie Toyne-Sewell

Managing Partner, Healthcare & Life Sciences, Instinctif Partners

Robert Tansley

Robert Tansley

Partner, Cambridge Innovation Capital

Ex-Officio

 Steve Bates OBE

Steve Bates OBE

Chief Executive Officer, BIA

Company Secretary

Nick Gardiner

Nick Gardiner

Chief Operating Officer, BIA